Видео с ютуба Dr Eunice Wang

Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO...

Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO...

Dr. Eunice Wang Discusses the Latest Advances in Menin Inhibitor Research

Decision-Making in AML: What's Next After Relapse I Dr. Eunice Wang - MRD Status #AML

Dr. Eunice Wang discusses Secondary MDS

What Key Tests Do You Need Before Choosing an AML Treatment?

Dr Ravi Vij MD, is Discussing with Dr. Eunice Wang MD, on Acute Myeloid Leukemia:Targeted Therapies

Shared Decision-Making, Advice for Partnering With Your AML Team

Одобрение FDA препарата Зифтомениб (KOMET-001) при остром миелоидном лейкозе (ОМЛ) с мутацией NPM...

The use of olutasidenib in R/R AML: an analysis of outcomes by number of prior treatment regimens

Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy

Where Do Clinical Trials Fit Into an AML Treatment Plan?

Eunice Wang, MD, talks about the challenges in treating elderly patients with AML

Real-world effectiveness and safety of CPX-351 in patients with secondary AML

Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients

Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML

Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL

Eunice Wang, MD, on the role of nivolumab maintenance in high-risk AML patients

Eunice Wang, MD, shares what we've learned about gilteritinib since the 2017 ASCO Annual Meeting

Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment